Soliton, Inc. announced the appointment of Niquette Hunt to its Board of Directors. Ms. Hunt currently serves as President and CEO of Candesant Biomedical. Ms. Hunt brings more than 25 years of general management and commercialization experience leading consumer product and biotechnology companies. Coming out of line management in both large corporations and start-ups, Ms. Hunt has proven her ability to drive significant growth on a variety of businesses across multiple industries. Ms. Hunt founded Candesant Biomedical in 2016 to develop a novel, non-invasive treatment for those who suffer from excessive sweating. She has guided the company through product development, Series A financing and is now focused on pre commercialization efforts targeting the $2 billion market opportunity. Prior to Candesant, Ms. Hunt was on the executive management team that took Revance Therapeutics public raising over $250 million in the IPO and follow-on financings. Ms. Hunt started her career at Procter & Gamble and Warner Lambert where she managed market leading brands such as Head and Shoulders and Lubriderm.